血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析*

doi:10.3969/j.issn.1672-5069.2022.06.006

实用肝脏病杂志 ›› 2022, Vol. 25 ›› Issue (6): 780-783.doi: 10.3969/j.issn.1672-5069.2022.06.006

血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*

吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁

710004 西安市西安交通大学第二附属医院感染病科

收稿日期:2022-03-28 出版日期:2022-11-10 发布日期:2022-11-22
通讯作者: 党双锁,E-mail: dang212@126.com
作者简介:吴凤萍,女,32岁,助理研究员。主要从事聚乙二醇干扰素-α治疗慢性乙型肝炎相关研究。E-mail: wfp612526@163.com
基金资助:
^*陕西省重点研发计划社会发展领域一般项目(编号:2020SF-297)

Serum B-cell activating factor levels in predicting antiviral response of pegylated interferon alpha in inactive HBsAg carriers

Wu Fengping, Cui Dandan, Wang Yikai, et al.

Department of Infectious Diseases, Second Affiliated Hospital, Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China

Received:2022-03-28 Online:2022-11-10 Published:2022-11-22

摘要/Abstract

摘要： 目的探讨血清B细胞活化因子(BAFF)预测聚乙二醇干扰素-α(Peg-IFN-α)治疗非活动性HBsAg携带者(IHCs)临床治愈的效能。方法 2018年1月～2020年8月我院诊治的IHCs 54例,给予Peg-IFN-α治疗48 w,再随访24 w。采用ELISA法检测血清BAFF,应用Logistic回归分析影响临床治愈的因素,应用受试者工作特征曲线(ROC)及其曲线下面积(AUC)评价血清BAFF预测临床治愈的效能。结果在72 w末,24例(44.4%)患者获得临床治愈,30例未获得临床治愈;治愈组与未治愈组基线血清BAFF水平分别为(670.9±105.9)pg/mL和(612.7±183.8)pg/mL,差异无统计学意义(P>0.05);在治疗12 w和24 w时,治愈组血清BAFF水平分别为(805.8±197.6)pg/mL和(895.3±227.4)pg/mL,显著高于未治愈组【分别为(675.3±190.8)pg/mL和(724.4±218.0)pg/mL,P 均<0.05】;多因素Logistic回归分析显示基线HBsAg定量、HBV DNA<20 IU/mL、治疗12 w和24 w时血清BAFF水平是影响临床治愈的独立因素;ROC分析显示,以Peg-IFN-α治疗12 w时血清BAFF水平大于704.3 pg/mL为截断点,其预测治疗应答的AUC=0.722, 敏感度为79.2%,特异度为66.7%,以24 w时血清BAFF水平大于741.9 pg/mL为截断点,其预测治疗应答的AUC=0.725,敏感度为75.0%,特异度为70.0%。结论应用Peg-IFN-α治疗IHCs可获得约40%的应答率,在治疗过程中监测血清BAFF水平逐渐升高的患者可能获得满意的治疗结果。

关键词: 慢性乙型肝炎, 非活动性乙型肝炎病毒表面抗原携带者, 聚乙二醇干扰素-α, B细胞活化因子, 治疗应答

Abstract: Objective The aim of this study was to investigate serum B-cell activating factor (BAFF) levels in predicting antiviral response of pegylated interferon alpha (Peg-IFN-α) in inactive HBsAg carriers(IHCs). Methods 54 IHCs were recruited in our hospital between January 2018 and August 2020,and all were treated with Peg-IFN-α for 48 weeks and followed-up for 24 weeks. Serum BAFF levels were measured by ELISA. The Logistic regression analysis was applied to analyze the factors affecting antiviral response, and the area under the receiver-operating characteristic curve (AUC) were applied to evaluate the performance of serum BAFF levels in predicting antiviral response. Results At the end of 72 weeks, the complete response (CR) was obtained in 24 cases (44.4%), and were not obtained in 30 cases (55.6%); there was no significant difference as respect to baseline serum BAFF levels [(670.9±105.9) pg/mL vs. (612.7±183.8)pg/mL, P>0.05] between the two groups; at the end of 12 weeks and 24 weeks, serum BAFF levels in responders were (805.8±197.6)pg/mL and (895.3±227.4)pg/mL, both significantly higher than [(675.3±190.8)pg/mL and (724.4±218.0)pg/mL, respectively, P<0.05] in non-responders; the multivariate Logistic regression analysis showed that baseline serum HBsAg, HBV DNA<20 IU/mL, serum BAFF levels at week 12 and week 24 were the independent factors impacting the antiviral response; the ROC analysis demonstrated that the AUC=0.722, with the sensitivity (Se) of 79.2% and specificity (Sp) of 66.7%, when serum BAFF level greater than 704.3 pg/mL at week 12 was set as the cut-off-value, and the AUC=0.725, with Se of 75.0% and Sp of 70.0%, when serum BAFF level greater than 741.9 pg/mL at week 24 was set as the cut-off-value in predicting antiviral response in patients receiving Peg-IFN-α treatment. Conclusion The CR is nearly 40% in IHCs receiving Peg-IFN-α treatment, and the surveillance of serum BAFF levels might guide the regimen going or stopping.

Key words: Hepatitis B, Inactive HBsAg carriers, Pegylated interferon-alpha, B-cell activating factor, Response

吴凤萍, 崔丹丹, 王怡恺, 李梅, 刘晨瑞, 南希, 贾晓黎, 党双锁. 血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 780-783.

Wu Fengping, Cui Dandan, Wang Yikai, et al.. Serum B-cell activating factor levels in predicting antiviral response of pegylated interferon alpha in inactive HBsAg carriers[J]. Journal of Practical Hepatology, 2022, 25(6): 780-783.

参考文献

[1] Sakai J, Akkoyunlu M. The role of BAFF system molecules in host response to pathogens. Clin Microbiol Rev, 2017, 30(4): 991-1014.
[2] Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol, 2018, 9: 2285.
[3] Han Q, Yang C, Li N, et al. Association of genetic variation in B-cell activating factor with chronic hepatitis B virus infection. Immunol Lett, 2017, 188: 53-58.
[4] Sene D, Limal N, Ghillani-Dalbin P, et al. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford), 2007, 46(1): 65-69.
[5] 王贵强,王福生,成军等.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):389-400.
[6] Terrault NA, Lok A, Mcmahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology, 2018, 67(4): 1560-1599.
[7] 王贵强,段钟平,王福生等.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):9-32.
[8] Invernizzi F, Vigano M, Grossi G, et al. The prognosis and management of inactive HBV carriers. Liver Int, 2016, 36(Suppl 1): 100-104.
[9] Mcmahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology, 2009, 49(Suppl 5): S45-S55.
[10] Chu CM, Liaw YF. Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int, 2007, 1(2): 311-315.
[11] Chen JD, Yang HI, Iloeje UH, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology, 2010, 138(5): 1747-1754.
[12] Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology, 2008, 135(2): 459-467.
[13] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2): 370-398.
[14] Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology, 2017, 66(4): 1058-1066.
[15] Tan G, Song H, Xu F, et al. When hepatitis B virus meets interferons. Front Microbiol, 2018, 9: 1611.
[16] Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis, 2016, 20(4): 645-665.
[17] Lake-Bakaar G, Jacobson I, Talal A. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol, 2012, 170(2): 231-237.
[18] Yang C, Li N, Wang Y, et al. Serum levels of B-cell activating factor in chronic hepatitis B virus infection: association with clinical diseases. J Interferon Cytokine Res, 2014, 34(10): 787-794.
[19] Khlaiphuengsin A, Chuaypen N, Hirankarn N, et al. Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Asian Pac J Allergy Immunol, 2021,39:129-135.
[20] Lake-Bakaar G, Jacobson I, Talal A. B cell activating factor (BAFF) in the natural history of chronic hepatitis C virus liver disease and mixed cryoglobulinaemia. Clin Exp Immunol, 2012, 170(2): 231-237.

血清BAFF预测聚乙二醇干扰素-α治疗非活动性HBsAg携带者临床治愈的效能分析^*

Serum B-cell activating factor levels in predicting antiviral response of pegylated interferon alpha in inactive HBsAg carriers

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李向阳, 丁光伟, 靳铭. 恩替卡韦治疗慢性乙型肝炎合并NAFLD患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 776-779.
[2]	齐孝安, 卢金喜, 袁林. 慢性乙型肝炎患者降钙素基因相关肽和α-干扰素-λ4基因多态性对α-干扰素治疗应答的影响^*[J]. 实用肝脏病杂志, 2022, 25(6): 784-787.
[3]	王玉珊, 孔银, 刘元元, 刘天府, 麻爱娣, 张亚萍, 李永芳, 张岭漪. 不同转换治疗策略对经治的低病毒血症慢性乙型肝炎患者疗效的影响:单中心回顾性研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 633-636.
[4]	徐欢, 谭钧元, 黄荷, 董丹丹. 聚乙二醇干扰素α-2a联合恩替卡韦治疗慢性乙型肝炎患者疗效及其外周血单个核细胞TLR4和B7-H1表达变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 637-640.
[5]	王春莹, 屈耀宁, 乔炜, 刘静静, 胡颖辉. 恩替卡韦治疗慢性乙型肝炎患者血清HBV cccDNA和HBV pgRNA水平变化^*[J]. 实用肝脏病杂志, 2022, 25(5): 641-644.
[6]	贾婷, 李俊义, 张秀灵, 高斯媛, 杨婧, 杨晓冬. 恩替卡韦联合聚乙二醇干扰素α-2b治疗低水平血清HBsAg阳性的慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 488-491.
[7]	刘雨莹, 张娇珍, 周海娟, 潘芳蝶, 黎才丽, 钟昌宝. 替诺福韦治疗不同HBV基因型慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 492-495.
[8]	汤磊, 彭蕾, 叶珺, 张振华, 邹桂舟. 影响慢性乙型肝炎患者进展为肝硬化的多因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 538-541.
[9]	黄俊榕, 吴昌儒, 吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 327-330.
[10]	邹东花, 秘建威, 李玉苓, 赵森. 阿德福韦酯分别联合恩替卡韦或替诺福韦治疗rtA181V/T单位点突变的慢性乙型肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 331-334.
[11]	罗珂, 丁莉, 刘美. 慢性乙型肝炎患者血清miR-21和miR-148b水平变化及其预测肝组织炎症分级和纤维化分期价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 335-338.
[12]	王广丽, 徐欢, 董丹丹, 黄荷. 慢性乙型肝炎患者血清HBV恩替卡韦耐药基因突变模式调查^*[J]. 实用肝脏病杂志, 2022, 25(3): 339-342.
[13]	严兆兰, 祖红梅, 蔡长霞, 魏巍. 血清低水平丙氨酸氨基转移酶的HBV感染者临床特征分析^*[J]. 实用肝脏病杂志, 2022, 25(3): 343-346.
[14]	李春花, 李忠新, 张春雷, 曾学辉, 陈甜甜, 宋林立. 不同肝纤维化程度的慢性乙型肝炎患者血清FGF-21、PDGF-BB和FBRS水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 347-350.
[15]	姜悦萌, 马于琪, 阚春明, 尹华发. 应用核苷(酸)类治疗慢性乙型肝炎患者早期肾功能的变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 351-354.